BCPS Therapeutic Decision-Making & Patient Management 4

Question 1

A patient with type 2 diabetes, BMI of 41 kg/m², and a recent MI 6 months ago requires glucose-lowering therapy beyond metformin. Which agent provides the MOST cardiovascular benefit?

Accepted Answer

Empagliflozin

Answer

Empagliflozin has demonstrated significant reductions in cardiovascular death and HF hospitalization in the EMPA-REG OUTCOME trial, making it preferred in patients with established ASCVD.

Question 2

A patient with community-acquired pneumonia (CAP) is admitted to the ICU with no Pseudomonas risk factors. Which empiric antibiotic regimen is most appropriate?

Accepted Answer

Beta-lactam plus azithromycin or respiratory fluoroquinolone

Answer

IDSA/ATS guidelines recommend combination therapy for severe CAP requiring ICU admission: a beta-lactam (ceftriaxone or ampicillin-sulbactam) plus a macrolide or monotherapy with a respiratory fluoroquinolone.

Question 3

A 60-year-old female with osteoporosis and a T-score of -2.8 at the femoral neck has been on alendronate for 5 years. A drug holiday is being considered. What is the appropriate FRAX threshold to consider a holiday?

Accepted Answer

10-year hip fracture risk <3% and major fracture risk <20%

Answer

A drug holiday after 5 years of oral bisphosphonate therapy is appropriate for patients at lower fracture risk (hip fracture risk <3% and major osteoporotic fracture risk <20%), where the residual effect provides continued protection.

Question 4

A patient is prescribed linezolid for VRE endocarditis. Which concurrent medication poses the MOST significant pharmacodynamic drug interaction risk?

Accepted Answer

Sertraline

Answer

Linezolid is a weak MAO inhibitor; combining it with serotonergic agents like sertraline risks serotonin syndrome, a potentially life-threatening pharmacodynamic interaction.

Question 5

In a patient with Clostridium difficile infection (CDI) that is severe and a second recurrence, which is the PREFERRED treatment option?

Accepted Answer

Fidaxomicin 200 mg twice daily for 10 days

Answer

IDSA guidelines recommend fidaxomicin for recurrent CDI over vancomycin due to its superior sustained clinical cure rates and lower recurrence risk.

(BCPS) Board Certified Pharmacotherapy Specialist Practice Test

(BCPS) Board Certified Pharmacotherapy Specialist Practice Test

BCPS Therapeutic Decision-Making & Patient Management 4